Replimune Group, Inc.REPL stock score: 41/100

$19.23 · -2.93% · Scored Nov 19, 2026

Technical
62
Fundamental
36
News
53

The reading

Replimune Group (REPL) scores 41 out of 100, which reads weak, higher than 28% of Healthcare stocks and 25% of the 4,118 US stocks we score.

The composite weights fundamentals 80% and technicals 20%: fundamentals read 36, technicals 62.

Among the fundamentals, Quick Ratio at 100 and Current Ratio at 100 score highest, while Free Cash Flow Yield at 0 weighs the most against it.

On the daily chart, trend-following indicators average 61 and contrarian oscillators 45.

News sentiment is neutral at 53; it is shown, not counted in the composite.

Since Aug 22, 2026 the composite has ranged from 38 to 51, and it is down 8 points over the period.

About Replimune Group

Replimune (REPL) is a biotechnology company that develops oncolytic immunotherapies, which use a modified herpes simplex virus to infect and destroy tumor cells while prompting the immune system to attack cancer elsewhere in the body. Its first product, Tudriqev, also known as RP1 or vusolimogene oderparepvec, received accelerated approval from the U.S. Food and Drug Administration for use with Bristol Myers Squibb’s Opdivo in patients with advanced melanoma whose disease has progressed after anti-PD-1 immunotherapy. Continued approval depends on results from an ongoing confirmatory Phase three trial. Tudriqev is injected directly into tumors by physicians at cancer centers. Replimune is also developing other candidates from the same platform, including RP2, for additional solid tumors. The company earns revenue from sales of Tudriqev and funds its research largely through cash raised from investors.

In advanced melanoma, Replimune competes with Iovance Biotherapeutics’ cell therapy and with drugs and combinations from Bristol Myers Squibb, Merck and other large drugmakers, as well as Amgen’s Imlygic, another oncolytic virus therapy. Its edge rests on an approved product for patients with few remaining options and a platform that may apply to other tumors that are hard to treat. Investors who follow REPL stock tend to watch the commercial launch of Tudriqev, including the number of treating centers and quarterly sales. Results from the confirmatory trial are closely followed. Data from its other programs, cash runway, operating expenses and the need for additional funding are other factors.

What’s driving the score

The strongest and weakest of the scorers that count toward REPL’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.

Fundamental

36

Pulling it up

  • Quick ratio measures a company's ability to meet short-term obligations with liquid assets.

  • Current assets divided by current liabilities: the ability to pay short-term bills.

  • Price target score compares the current stock price to analyst consensus targets.

Holding it back

  • Free cash flow yield is free cash flow divided by market value: the cash a business generates for each dollar of its price.

  • Return on Equity (ROE) measures how efficiently a company generates profits from shareholder equity.

  • Return on Assets (ROA) shows how efficiently a company uses its assets to generate profit.

26 weighted scorers; 13 had no data today and are left out rather than counted as zero.

Technical · daily

61

Pulling it up

  • Exponential Moving Average (100-period) provides a responsive long-term trend view.

  • Exponential Moving Average (200-period) is a crucial long-term trend indicator that reacts faster than SMA-200.

  • Simple Moving Average (100-period) provides a longer-term perspective on price trends.

Holding it back

  • Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.

  • Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.

  • Simple Moving Average (10-period) smooths price action over 10 periods.

62 weighted scorers; 3 had no data today and are left out rather than counted as zero.

News · shown, not counted

Global News
53

Technical score by timeframe

ChartScoreWeight
Hourly361
Daily613
Weekly682
Monthly722

Composite score, last 90 days

05010041Aug 22, 2026Nov 19, 2026Aug 22, 2026: 49Aug 23, 2026: 48Aug 24, 2026: 49Aug 25, 2026: 50Aug 26, 2026: 49Aug 27, 2026: 49Aug 28, 2026: 48Aug 29, 2026: 49Aug 30, 2026: 49Aug 31, 2026: 48Sep 1, 2026: 49Sep 2, 2026: 49Sep 3, 2026: 51Sep 4, 2026: 47Sep 5, 2026: 47Sep 6, 2026: 47Sep 7, 2026: 47Sep 8, 2026: 47Sep 9, 2026: 45Sep 10, 2026: 44Sep 11, 2026: 44Sep 12, 2026: 44Sep 13, 2026: 44Sep 14, 2026: 45Sep 15, 2026: 44Sep 16, 2026: 44Sep 17, 2026: 45Sep 18, 2026: 46Sep 19, 2026: 45Sep 20, 2026: 45Sep 21, 2026: 45Sep 22, 2026: 47Sep 23, 2026: 47Sep 24, 2026: 45Sep 25, 2026: 43Sep 26, 2026: 43Sep 27, 2026: 43Sep 28, 2026: 43Sep 29, 2026: 46Sep 30, 2026: 47Oct 1, 2026: 48Oct 2, 2026: 47Oct 3, 2026: 48Oct 4, 2026: 48Oct 5, 2026: 46Oct 6, 2026: 48Oct 7, 2026: 48Oct 8, 2026: 46Oct 9, 2026: 48Oct 10, 2026: 47Oct 11, 2026: 47Oct 12, 2026: 47Oct 13, 2026: 43Oct 14, 2026: 41Oct 15, 2026: 41Oct 16, 2026: 39Oct 17, 2026: 39Oct 18, 2026: 39Oct 19, 2026: 39Oct 20, 2026: 40Oct 21, 2026: 41Oct 22, 2026: 42Oct 23, 2026: 40Oct 24, 2026: 40Oct 25, 2026: 40Oct 26, 2026: 44Oct 27, 2026: 47Oct 28, 2026: 48Oct 29, 2026: 50Oct 30, 2026: 49Oct 31, 2026: 49Nov 1, 2026: 49Nov 2, 2026: 50Nov 3, 2026: 50Nov 4, 2026: 49Nov 5, 2026: 48Nov 6, 2026: 49Nov 7, 2026: 48Nov 8, 2026: 48Nov 10, 2026: 49Nov 11, 2026: 48Nov 12, 2026: 38Nov 13, 2026: 41Nov 14, 2026: 41Nov 15, 2026: 42Nov 16, 2026: 41Nov 17, 2026: 41Nov 18, 2026: 41Nov 19, 2026: 41
Show the daily numbers
DateComposite
Nov 19, 202641
Nov 18, 202641
Nov 17, 202641
Nov 16, 202641
Nov 15, 202642
Nov 14, 202641
Nov 13, 202641
Nov 12, 202638
Nov 11, 202648
Nov 10, 202649
Nov 8, 202648
Nov 7, 202648
Nov 6, 202649
Nov 5, 202648
Nov 4, 202649
Nov 3, 202650
Nov 2, 202650
Nov 1, 202649
Oct 31, 202649
Oct 30, 202649
Oct 29, 202650
Oct 28, 202648
Oct 27, 202647
Oct 26, 202644
Oct 25, 202640
Oct 24, 202640
Oct 23, 202640
Oct 22, 202642
Oct 21, 202641
Oct 20, 202640
Oct 19, 202639
Oct 18, 202639
Oct 17, 202639
Oct 16, 202639
Oct 15, 202641
Oct 14, 202641
Oct 13, 202643
Oct 12, 202647
Oct 11, 202647
Oct 10, 202647
Oct 9, 202648
Oct 8, 202646
Oct 7, 202648
Oct 6, 202648
Oct 5, 202646
Oct 4, 202648
Oct 3, 202648
Oct 2, 202647
Oct 1, 202648
Sep 30, 202647
Sep 29, 202646
Sep 28, 202643
Sep 27, 202643
Sep 26, 202643
Sep 25, 202643
Sep 24, 202645
Sep 23, 202647
Sep 22, 202647
Sep 21, 202645
Sep 20, 202645
Sep 19, 202645
Sep 18, 202646
Sep 17, 202645
Sep 16, 202644
Sep 15, 202644
Sep 14, 202645
Sep 13, 202644
Sep 12, 202644
Sep 11, 202644
Sep 10, 202644
Sep 9, 202645
Sep 8, 202647
Sep 7, 202647
Sep 6, 202647
Sep 5, 202647
Sep 4, 202647
Sep 3, 202651
Sep 2, 202649
Sep 1, 202649
Aug 31, 202648
Aug 30, 202649
Aug 29, 202649
Aug 28, 202648
Aug 27, 202649
Aug 26, 202649
Aug 25, 202650
Aug 24, 202649
Aug 23, 202648
Aug 22, 202649

Key facts

Market cap
$1.8B
Sector
Healthcare
Industry
Biotechnology
Beta
0.93
Risk grade (1–10)
8
Next earnings
Oct 28, 2026

Questions

What is REPL's stock rating today?

REPL scores 41/100 (Weak) as of Nov 19, 2026: technical 62, fundamental 36, and news sentiment 53, which is shown but not counted. Scores are recomputed every night.

What does Replimune Group do?

Replimune (REPL) is a biotechnology company that develops oncolytic immunotherapies, which use a modified herpes simplex virus to infect and destroy tumor cells while prompting the immune system to attack cancer elsewhere in the body. Its first product, Tudriqev, also known as RP1 or vusolimogene oderparepvec, received accelerated approval from the U.S.

Is REPL stock a buy?

The score is not a buy or sell recommendation. A 41 says the technical and fundamental signals we measure lean weak today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.

How is the REPL score calculated?

88 weighted scorers feed it today: 26 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.

Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.

Embed this score

A badge for a blog post, newsletter or README. It updates every night and links back here. More badges

REPL stock score

HTML

<a href="https://stocksscores.com/stocks/repl/"><img src="https://stocksscores.com/stocks/repl/badge.svg" alt="REPL stock score" height="20"></a>

Markdown

[![REPL stock score](https://stocksscores.com/stocks/repl/badge.svg)](https://stocksscores.com/stocks/repl/)